FDA Brief

Warning letters Drugs

FDA warning letter to

Catalent Indiana, LLC

High riskIssued Nov 20, 2025Posted Dec 11, 2025Office of Manufacturing Quality

Catalent Indiana's Bloomington plant released sterile vials contaminated with mammalian hair and failed to investigate, FDA says.

What happened

FDA inspected the Catalent Indiana drug manufacturing facility in Bloomington, Indiana, from June 23 to July 14, 2025. Investigators found that since August 2023 the firm recorded more than 20 deviations for mammalian hair in or around the stopper area of vials, sometimes touching the drug product, and did not investigate them promptly or well. The firm also failed to investigate batches of media fills (test runs that stand in for real product) that were terminated, and released contaminated batches to customers, leading to recalls after a September 26, 2025 call with FDA.

What FDA found

  1. The firm did not thoroughly investigate batch failures and discrepancies, including more than 20 hair-contamination deviations dating to August 2023, and its investigations often lacked data for the stated root cause and did not check whether fixes worked.

    21 CFR 211.192
  2. The quality unit released commercial batches with visible mammalian hair after removing some contaminated units, rather than rejecting the batches, and customers later found hair and rejected them.

    21 CFR 211.192
  3. More than five media fill batches were terminated since November 2023, and for two of them no deviation or investigation was opened at the time as the firm's own procedures required.

    21 CFR 211.192
  4. The visual inspection program did not set limits or track trends for individual defect types such as hair, glass and atypical particulate, relying instead on three broad categories.

    21 CFR 211.113(b)
  5. The firm made quality decisions on stoppers using pre-shipment samples sent by the supplier instead of sampling the containers itself after receipt, and did not extend enhanced sampling to all stopper suppliers.

    21 CFR 211.113(b)
  6. Surfaces in the decontamination process could be hidden from exposure and were disturbed by interventions, and contact plates used on irregular product-contact surfaces are less effective than swabs at finding contamination.

    21 CFR 211.113(b)

What FDA wants

FDA asks the company to respond in writing within 15 working days describing corrections and to supply independent assessments, remediation plans and data on investigations, corrective actions, stopper supplier quality and contamination hazards. FDA also asks the firm to arrange a teleconference to discuss its corrective actions and to contact its Drug Shortages Staff if supply may be disrupted.

Who should pay attention

  • companies that buy finished sterile drug products from this contract manufacturer
  • drugmakers using this site for sterile fill-finish
  • quality teams at other Catalent sites acquired by Novo Nordisk

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  2. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  3. Fresenius Kabi USA LLC

    FDA warns Fresenius Kabi USA over manufacturing failures for sterile injectables at Melrose Park, including endotoxin contamination and media fill failures.

    High risk
  4. Jabil Inc.

    FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.

    High risk